Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Randomized, Open Label, Safety and Efficacy Study Evaluating Kamuvudine-8 (K8) for the Treatment of Patients With Geographic Atrophy

NCT06164587 is registered in ClinicalTrials.gov with Inflammasome Therapeutics as lead sponsor.

NCT NCT06164587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06164587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Randomized, Open Label, Safety and Efficacy Study Evaluating Kamuvudine-8 (K8) for the Treatment of Patients With Geographic Atrophy
Lead sponsor
Inflammasome Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
April 18, 2024
Completion date
May 15, 2026
Enrollment
30 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, geographic atrophy